Preprint Concept Paper Version 2 This version is not peer-reviewed

Infection-Genomics of COVID-19: Are Some Communities Resistant?

Version 1 : Received: 18 April 2020 / Approved: 19 April 2020 / Online: 19 April 2020 (01:35:58 CEST)
Version 2 : Received: 2 May 2020 / Approved: 4 May 2020 / Online: 4 May 2020 (19:12:33 CEST)
Version 3 : Received: 16 May 2020 / Approved: 17 May 2020 / Online: 17 May 2020 (14:51:39 CEST)

How to cite: Kini, R.M.; Kundu, S. Infection-Genomics of COVID-19: Are Some Communities Resistant?. Preprints 2020, 2020040310 (doi: 10.20944/preprints202004.0310.v2). Kini, R.M.; Kundu, S. Infection-Genomics of COVID-19: Are Some Communities Resistant?. Preprints 2020, 2020040310 (doi: 10.20944/preprints202004.0310.v2).

Abstract

The 2019-Novel Coronavirus has currently gripped the world in terror, affecting 210 countries and territories as of April 29, 2020. Originating from Wuhan, Hubei province, China, the virus has spread so rapidly throughout the world and has already claimed 218,000 lives and is currently afflicting 3.14 million people. The US has over 1.03 million confirmed cases of COVID-19, followed by Spain, Italy, France, UK, Germany, Turkey, Russia, Iran, and China. On careful inspection of the COVID-19 statistics, a peculiar unsettling trend becomes apparent. Western European countries and the US appear to have difficulties in overcoming the catastrophe. In contrast, countries in East Asia, Middle East and mid-Europe have sorted out the situation. Here, we will highlight this trend and propose the importance of infection-genomics (sankramikogenomics), in understanding the susceptibility to COVID-19 and the severity of disease progress. More detailed evaluation may also identify more susceptible populations. Such differences are due to variations in structure or tissue-specific expression (alternate splicing and accessibility) of the target receptors. So, we will highlight mere 12-fold lower affinity is insufficient to ignore CD147, as interactions occur between tens of spike proteins and equal number of cell surface ACE2 and/or CD147. Similar to pharmacogenomics to drug development and precision medicine, Sankramikogenomics will become an important field in other infectious diseases and pathogenicity.

Subject Areas

ACE2; Spike protein; SARS-CoV2; death rate; polymorphism; isoform variant; CD157, sankramikogenomics

Comments (1)

Comment 1
Received: 4 May 2020
Commenter: R. Manjunatha Kini
Commenter's Conflict of Interests: Author
Comment: In this version of manuscript, new details of COVID-19 target recepror- CD147 are being added. Also, statistical data has been updated.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.